AR103520A1 - Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica y composiciones farmacéuticas multiparticuladas que los contienen - Google Patents
Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica y composiciones farmacéuticas multiparticuladas que los contienenInfo
- Publication number
- AR103520A1 AR103520A1 ARP160100201A ARP160100201A AR103520A1 AR 103520 A1 AR103520 A1 AR 103520A1 AR P160100201 A ARP160100201 A AR P160100201A AR P160100201 A ARP160100201 A AR P160100201A AR 103520 A1 AR103520 A1 AR 103520A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- proton pump
- enteric
- composition
- multiparticulate pharmaceutical
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 239000008188 pellet Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 5
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract 3
- 108010083204 Proton Pumps Proteins 0.000 abstract 3
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 3
- 239000000612 proton pump inhibitor Substances 0.000 abstract 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 abstract 2
- 229960001259 diclofenac Drugs 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 abstract 1
- 229960004770 esomeprazole Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 abstract 1
- 229960000381 omeprazole Drugs 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica de estructura benzimidazólica, útiles para preparar composiciones farmacéuticas multiparticuladas de uso oral que comprende las siguientes etapas: I) recubrir núcleos de celulosa pura con una suspensión hidroalcohólica que contiene el inhibidor de la bomba protónica, un aminoácido dibásico y polivinilpirrolidona; II) aislar los núcleos de celulosa pura recubiertos obtenidos en la Etapa I; III) aplicar un recubrimiento entérico a las partículas obtenidas en la Etapa II anterior; y IV) secar las partículas obtenidas en la Etapa III anterior separar por tamaño. Una composición farmacéutica multiparticulada bajo la forma de comprimidos de desintegración oral, de polvo para suspensión de uso oral o de cápsulas de uso oral, que comprende pellets entéricos, con un diámetro promedio comprendido entre 350 y 500 mm y un contenido de un inhibidor de la bomba protónica de estructura benzimidazólica superior al 10.5%, obtenidos de acuerdo al procedimiento anterior. Reivindicación 22: Composición según cualquiera de las reivindicaciones 16 a 21, caracterizada porque los pellets del inhibidor de la bomba protónica están asociados en la misma composición con microcápsulas entéricas de diclofenac. Reivindicación 23: Composición según la reivindicación 22, caracterizada porque el contenido de inhibidor de la bomba protónica en la composición está comprendido entre 10 y 40 mg y el contenido de diclofenac está comprendido entre 25 y 100 mg. Reivindicación 24: Composición según una de las reivindicaciones 22 ó 23, caracterizada porque el inhibidor de la bomba protónica es omeprazol o esomeprazol.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2015/056982 WO2016155786A1 (en) | 2015-03-31 | 2015-03-31 | Enteric-coated pellets containing a proton pump inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
AR103520A1 true AR103520A1 (es) | 2017-05-17 |
Family
ID=53724266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100201A AR103520A1 (es) | 2015-03-31 | 2016-01-26 | Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica y composiciones farmacéuticas multiparticuladas que los contienen |
Country Status (17)
Country | Link |
---|---|
US (2) | US10786458B2 (es) |
EP (1) | EP3277267B1 (es) |
CN (1) | CN107530294B (es) |
AR (1) | AR103520A1 (es) |
AU (1) | AU2015389109B2 (es) |
BR (1) | BR112017020790A2 (es) |
CA (1) | CA2977168C (es) |
CL (1) | CL2017002424A1 (es) |
CO (1) | CO2017010900A2 (es) |
HK (1) | HK1245087A1 (es) |
MX (1) | MX2017012643A (es) |
PH (1) | PH12017501363B1 (es) |
RU (1) | RU2679652C1 (es) |
SG (1) | SG11201706209TA (es) |
UA (1) | UA120715C2 (es) |
UY (1) | UY36512A (es) |
WO (1) | WO2016155786A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017012539A (es) | 2015-03-31 | 2018-09-28 | Mutabilis | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
AU2017310506B2 (en) | 2016-08-11 | 2019-11-21 | Dmk Pharmaceuticals Corporation | Drug compositions |
US11564910B2 (en) | 2017-12-08 | 2023-01-31 | Adamis Pharmaceuticals Corporation | Drug compositions |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8404808L (sv) | 1983-10-03 | 1985-04-04 | Avner Rotman | Mikrokapslat lekemedel i sot matris |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
JP3069458B2 (ja) | 1992-01-29 | 2000-07-24 | 武田薬品工業株式会社 | 口腔内崩壊型錠剤およびその製造法 |
US6328994B1 (en) * | 1998-05-18 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
ATE249218T1 (de) * | 1999-01-06 | 2003-09-15 | Tecnimede Sociedade Tecnico Medicinal Sa | Cyclodextrin einschlusskomplexe mit aminosäuresalzen von benzimidazolderivaten, deren herstellung, sowie diese enthaltende pharmazeutische zusammensetzungen |
US6228400B1 (en) * | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
WO2004062552A2 (en) | 2003-01-09 | 2004-07-29 | Galephar M/F | Pharmaceutical composition containing a nsaid and a benzimidazole derivative |
ES2338009T3 (es) * | 2003-07-11 | 2010-05-03 | Astrazeneca Ab | Composicion solida que comprende un inhibidor de la bomba de protones. |
CN1263450C (zh) * | 2005-01-20 | 2006-07-12 | 北京科信必成医药科技发展有限公司 | 奥美拉唑及其衍生物的口腔崩解片及其制备工艺 |
CN100393304C (zh) * | 2005-02-28 | 2008-06-11 | 上海艾力斯医药科技有限公司 | 一种包含酸不稳定药物的微细颗粒及其制剂 |
WO2006134611A1 (en) * | 2005-06-16 | 2006-12-21 | Hetero Drugs Limited | Compositions of antiulcerative substituted benzimidazoles |
EP1813275A1 (en) | 2005-12-20 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Lansoprazole orally disintegrating tablets |
US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
CN100490790C (zh) * | 2007-04-28 | 2009-05-27 | 杭州民生药业集团有限公司 | 一种奥美拉唑肠溶微丸胶囊及其制备方法 |
MX2010001071A (es) * | 2007-07-27 | 2010-03-09 | Depomed Inc | Formas de dosificacion retentivas gastricas pulsatiles. |
DE102008045339A1 (de) * | 2008-09-01 | 2010-03-04 | Stada Arzneimittel Ag | Pharmazeutisches Pellet |
US20120058194A1 (en) | 2010-08-27 | 2012-03-08 | Navin Vaya | Pharmaceutical formulations comprising substituted benzimidazole derivatives |
CN102526049A (zh) * | 2012-02-04 | 2012-07-04 | 神威药业有限公司 | 一种复方双氯芬酸钠缓释制剂及其制备方法 |
PL2827843T3 (pl) * | 2012-03-20 | 2016-11-30 | Sposób wytwarzania dojelitowych alginianowych mikrokapsułek poprzez żelowanie jonowe zawierających diklofenak lub jedną z jego soli oraz zawierającej je wielocząsteczkowej kompozycji farmaceutycznej |
-
2015
- 2015-03-31 UA UAA201710548A patent/UA120715C2/uk unknown
- 2015-03-31 AU AU2015389109A patent/AU2015389109B2/en not_active Ceased
- 2015-03-31 CN CN201580078504.8A patent/CN107530294B/zh not_active Expired - Fee Related
- 2015-03-31 BR BR112017020790-7A patent/BR112017020790A2/pt not_active Application Discontinuation
- 2015-03-31 CA CA2977168A patent/CA2977168C/en active Active
- 2015-03-31 WO PCT/EP2015/056982 patent/WO2016155786A1/en active Application Filing
- 2015-03-31 SG SG11201706209TA patent/SG11201706209TA/en unknown
- 2015-03-31 EP EP15741872.4A patent/EP3277267B1/en active Active
- 2015-03-31 MX MX2017012643A patent/MX2017012643A/es unknown
- 2015-03-31 RU RU2017133540A patent/RU2679652C1/ru active
- 2015-03-31 US US15/563,181 patent/US10786458B2/en active Active
-
2016
- 2016-01-08 UY UY0001036512A patent/UY36512A/es not_active Application Discontinuation
- 2016-01-26 AR ARP160100201A patent/AR103520A1/es unknown
-
2017
- 2017-07-28 PH PH12017501363A patent/PH12017501363B1/en unknown
- 2017-09-26 CL CL2017002424A patent/CL2017002424A1/es unknown
- 2017-10-26 CO CONC2017/0010900A patent/CO2017010900A2/es unknown
-
2018
- 2018-04-03 HK HK18104440.8A patent/HK1245087A1/zh unknown
-
2020
- 2020-08-26 US US17/003,233 patent/US20200390709A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PH12017501363A1 (en) | 2017-12-18 |
HK1245087A1 (zh) | 2018-08-24 |
CL2017002424A1 (es) | 2018-04-13 |
CN107530294B (zh) | 2021-11-30 |
RU2679652C1 (ru) | 2019-02-12 |
PH12017501363B1 (en) | 2017-12-18 |
SG11201706209TA (en) | 2017-10-30 |
EP3277267A1 (en) | 2018-02-07 |
US20180078505A1 (en) | 2018-03-22 |
CO2017010900A2 (es) | 2018-01-16 |
UY36512A (es) | 2016-08-31 |
UA120715C2 (uk) | 2020-01-27 |
CA2977168A1 (en) | 2016-10-06 |
CN107530294A (zh) | 2018-01-02 |
MX2017012643A (es) | 2018-08-01 |
CA2977168C (en) | 2020-01-28 |
US20200390709A1 (en) | 2020-12-17 |
EP3277267B1 (en) | 2021-01-06 |
US10786458B2 (en) | 2020-09-29 |
AU2015389109A1 (en) | 2017-08-17 |
BR112017020790A2 (pt) | 2018-06-26 |
WO2016155786A1 (en) | 2016-10-06 |
AU2015389109B2 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017010900A2 (es) | Pellets con recubrimiento entérico que contiene un inhibidor de bomba de protones | |
CO6300931A2 (es) | Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos | |
CO2019001895A2 (es) | Formulación novedosa para administración por vía oral | |
PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
BR112013020404A2 (pt) | formulações de l-mentol multiparticulado e métodos relacionados | |
PE20161373A1 (es) | Composiciones de liberacion retardada de linaclotida | |
EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
WO2014175917A8 (en) | Multiparticulate l-menthol formulations and related methods | |
DOP2017000294A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
DOP2012000300A (es) | Activadores de guanilato ciclase soluble | |
UY29193A1 (es) | Nuevas formulaciones de tabletas de liberación modificada para inhibidores de bomba de protón | |
AR080662A1 (es) | Forma de dosis oral solida con contenido de nanoparticulas y proceso de formulacion de la misma utilizando gelatina de pescado | |
CO2017012766A2 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
EA201290734A1 (ru) | Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта | |
EA031255B1 (ru) | Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения | |
MX2016007134A (es) | Composiciones farmaceuticas mejoradas de pimobendan. | |
BR112014032948A2 (pt) | cápsulas contendo timoquinona | |
PE20110583A1 (es) | Comprimidos de capecitabina de disgregacion rapida | |
BRPI0517933A (pt) | forma de dosagem farmacêutica sólida oral, processo para a preparação de uma forma de dosagem farmacêutica oral, método para aperfeiçoar a inibição de secreção de ácido gástrico, e, uso de uma forma de dosagem farmacêutica | |
CL2015003468A1 (es) | Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. | |
AR108231A1 (es) | Composiciones farmacéuticas orales de mesalazina | |
AR078951A1 (es) | Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea | |
PH12014501408A1 (en) | Immediate release multi unit pellet system | |
CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo | |
JP2015129124A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |